Vagus Nerve Stimulation Market Size, Share & Trends Analysis Report By Product (External VNS Device, Implantable VNS devices), By Application (Epilepsy, Depression, Others), By End User (Hospitals, Neurology clinics, Ambulatory Surgical Centers, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Vagus Nerve Stimulation Market Size & Growth Analysis

The global vagus nerve stimulation market size was valued at USD 575.81 million in 2025 and is projected to grow from USD 610.70 million in 2026 to USD 977.79 million by 2034, registering a CAGR of 6.06% during the forecast period from 2026 to 2034. North America dominated the vagus nerve stimulation market with a market share of 54.78% in 2025.

The global market comprises a diverse range of products, including external VNS devices and implantable VNS systems, designed to provide neuromodulation therapies. These devices are utilized across multiple clinical applications, such as epilepsy, depression, and other indications. Furthermore, VNS therapies are delivered through different healthcare settings, including hospitals, neurology clinics, ambulatory surgical centers, and other specialized facilities.

Application Insights

The epilepsy segment dominated the market in 2025, accounting for 58.89% revenue share. This growth is supported by the increasing adoption of closed-loop VNS systems that automatically adjust stimulation in response to real-time brain activity. This innovation enhances seizure control and patient safety, driving stronger clinical acceptance and sustained growth within the epilepsy treatment segment.

The depression segment is projected to grow at the fastest CAGR of 7.72% during the forecast period, owing to the integration of VNS therapy with advanced neuroimaging and AI-based mood tracking systems. These technologies enable personalized stimulation protocols, improving therapeutic outcomes and expanding VNS adoption in treatment-resistant depression.

Request Customizationto receive a tailored report.

Product Insights

The implantable VNS devices segment dominated the market in 2025. This dominance is augmented by the introduction of miniaturized, MRI-compatible implants that ensure long-term therapy with minimal interference during diagnostic imaging. These technological advancements enhance patient safety, device compatibility, and clinician confidence, reinforcing the widespread preference for implantable VNS systems.

The external VNS devices segment is expected to register the fastest CAGR of 9.05%. This growth is driven by the increasing availability of app-connected, user-controlled stimulation devices. These systems allow therapy adjustments and data tracking, improving convenience, treatment adherence, and expanding use among patients seeking non-surgical neuromodulation options.

End User Insights

The hospitals segment dominated the market with a revenue share of 39.74% in 2025. This growth is attributed to the establishment of specialized neurostimulation centers within hospitals, enabling multidisciplinary teams to perform complex VNS implantations and offer integrated post-operative care, thereby improving clinical outcomes and driving higher patient inflow.

The neurology clinics segment is estimated to grow at the fastest pace in 2026-2034, due to the rising adoption of outpatient-based VNS therapy programs supported by portable diagnostic tools. These advancements allow neurologists to deliver personalized stimulation adjustments in clinical settings, enhancing treatment efficiency and reducing dependence on hospital-based procedures.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America dominated the vagus nerve stimulation market in 2025, accounting for 54.78% market share. This dominance is attributed to the presence of major players such as LivaNova, electroCore, and MicroTransponder having strong regional operations. Their local R&D centers, faster FDA approvals, and extensive distribution networks ensure quicker access to advanced implantable and non-invasive VNS therapies.

A surge in healthcare providers recommending vagus nerve stimulation for epilepsy and treatment-resistant depression is a major factor driving market growth in the U.S. According to recent clinical surveys, more than 90% of neurologists and psychiatrists support VNS as an adjunct therapy for patients not responding to pharmaceutical treatments. This strong clinical acceptance is boosting device adoption and fueling sustained market growth across the country.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market

Asia Pacific is emerging as the fastest growing region with a CAGR of 8.21% from 2026 to 2034, owing to the rising prevalence of neurological disorders such as epilepsy, Alzheimer’s disease, and stroke-related complications. Rapid urbanization, changing lifestyles, and increasing stress levels have contributed to higher incidences of these conditions. The growing disease burden is driving demand for effective neuromodulation therapies like vagus nerve stimulation across the region.

In China, the inclusion of vagus nerve stimulation (VNS) in the national healthcare system is a key factor driving the VNS market growth. The government now recognizes VNS as an effective treatment for epilepsy and depression and has added it to national health insurance coverage. This policy makes VNS therapy more accessible to patients, increasing the market size. Additionally, the support from the government also motivates domestic and international companies to invest in the Chinese VNS market, boosting adoption and overall market growth.

Europe Market Insights

Europe’s vagus nerve stimulation market growth is driven by the increasing participation of regional research institutions in multi-center clinical trials exploring new VNS indications, enhancing clinical validation, and adoption. Furthermore, the growing reimbursement coverage for neurostimulation therapies across countries such as Germany, France, and the U.K. is improving patient access and accelerating market expansion.

In the UK, the vagus nerve stimulation (VNS) market is experiencing substantial growth, driven by increasing adoption in treating drug-resistant epilepsy and expanding applications in other neurological disorders. The National Health Service (NHS) has established commissioning policies that facilitate equitable access to VNS therapies across England and Wales. These policies ensure that patients with refractory epilepsy have access to VNS devices, which, in turn, contribute to market growth.

Latin America Market Insights

Latin America’s vagus nerve stimulation market growth is supported by the establishment of specialized neuromodulation programs in leading hospitals across Brazil and Mexico, fostering clinical expertise and awareness. Moreover, growing collaborations between local healthcare providers and international device manufacturers are facilitating technology transfer, regulatory approvals, and training initiatives, thereby improving accessibility to advanced VNS therapies in the region.

In Brazil, the vagus nerve stimulation market is growing due to the government’s increasing investment in neuroscience research and innovation hubs. These initiatives are promoting local clinical trials, encouraging physician training in neurostimulation techniques, and accelerating the introduction of advanced VNS devices into public and private healthcare systems across the country.

Middle East and Africa Market Insights

The Middle East and Africa vagus nerve stimulation market is expanding due to rising investments in advanced neurology centers in the UAE and Saudi Arabia, where hospitals are adopting advanced neurostimulation technologies. Furthermore, the increasing prevalence of traumatic brain injuries and stroke-related neurological complications is prompting greater clinical interest in VNS therapy as a complementary rehabilitation solution across the region.

In Saudi Arabia, the vagus nerve stimulation market is expanding due to the growing partnerships between international neurotechnology companies and local medical device distributors. These collaborations are enhancing the regional supply chain, ensuring faster regulatory approvals, and improving the availability of advanced VNS systems across both public and private healthcare institutions.

Competitive Landscape

The global market is consolidated, with a few major established players dominating the implantable vagus nerve stimulation segment. Established market players maintain their leadership through continuous product innovation, clinical trial pipeline, and strategic regulatory approvals. The major players in the market include LivaNova PLC, electroCore, Inc., MicroTransponder, Inc., Parasym Ltd, and BioControl Medical. These industry participants are focusing on strengthening their market position by securing FDA and CE mark approvals.

Senseonics Holdings, Inc.: An emerging market player

Tivic Health, a U.S.-based bioelectronic medicine company, is emerging in the global market with its development of non-invasive cervical VNS (ncVNS) devices.

• In May 2024, Tivic Health announced successful results from a pilot clinical trial showing their ncVNS intervention produced positive biological changes in the autonomic, cardiac, and central nervous systems.
• In June 2025, the company completed an Optimization Study aimed at refining device parameters for better autonomic nervous system modulation.

Through its non-invasive technology, Tivic Health is positioning itself as an emerging player in the VNS market.

List of Key and Emerging Players in Vagus Nerve Stimulation Market